HIV-1 protease-IN-13
HIV-1 protease-IN-13 (compound 18d) is a potent HIV-1 protease inhibitor with an IC50 value of 0.54 nM. HIV-1 protease-IN-13 also shows potent activity against HIV-1DRVRS (DRV-resistant mutation) and HIV-1NL4_3 variant (wild type) [1].
Product Specifications
UNSPSC
12352005
Target
HIV Protease
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/hiv-1-protease-in-13.html
Solubility
10 mM in DMSO
Smiles
OC1=C(O)C=C(CC(N[C@@H](CC2=CC=CC=C2)[C@H](O)CN(CC(C)C)S(C3=CC=C(OC)C=C3)(=O)=O)=O)C=C1
Molecular Formula
C29H36N2O7S
Molecular Weight
556.67
References & Citations
[1]Sihan Meng, et al. Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-Resistant HIV-1 variants. Bioorg Med Chem Lett. 2024 Feb 9:101:129651.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880008-500 1x 500 µL
MAGE A1 (MA454), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC700977-100 1x 100 µL
TGF-beta (1D11.16.8), CF770 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680017-100 1x 100 µL
Ep-CAM / CD326 (VU-1D9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details